Navigation Links
Contract Research Organization WCCT Global Welcomes Edward Kim as Executive Director, Early Clinical Development
Date:11/5/2013

Costa Mesa, Ca (PRWEB) November 05, 2013

WCCT Global (WCCTG) is pleased to announce and welcome Mr. Edward Kim as Executive Director, Early Clinical Development. Ed will be overseeing the WCCTG, Cypress and Costa Mesa Clinical Pharmacology Research Units. As a Contract Research Organization professional Mr. Kim has over 17 years of Early Phase clinical research experience in both academia and the site/CRO industry. Nearly 15 years of his career was with California Clinical Trials/Parexel International, where he served as Director of Clinical Operations. He was responsible for managing all clinical operations (Clinical Research Teams, Pharmacy, Laboratory, and Nursing) for their expanded 100+ beds across their 3 Phase I units. Mr. Kim has conducted over 400 clinical trials supporting CNS indications, Asian ethnobridging, “CSF-dynabridging” programs, and various specialized programs in healthy normal populations. When asked how Ed felt to be joining WCCT Global, he replied, “I am extremely excited to be joining this dynamic and growing organization, and look forward to leveraging my background and knowledge in this space to help WCCTG continue to grow.”

“This is another great addition to WCCT Global,” exclaimed Jon Rojas, WCCTG’s Chief Operating Officer, “because this service offering is part of WCCTG’s core business which continues to grow. Having team members like Mr. Kim is why we are contacted by sponsors all over the world to perform clinical studies in many different therapeutic areas.”

More about WCCT Global:
WCCT Global is a multi-site, full service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, “With compassion for people, we strive for tomorrow’s therapies to be available today” truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.

If you would like to request information how WCCT Global can assist your organization with your next clinical study, click here.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11300059.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Arizona State University secures defense contract
2. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
3. Local Woodinville Contractor, Washington State Kitchen and Bath, Combats Toxic Mold, Adhering to the Toughest Mold Protection Standards in the Nation with New Promotion
4. Collagenase for Dupuytrens contracture: Added benefit not proven
5. BMC awarded contract to study validity of primary care drug screening tools
6. Federal government renews contract for collecting and maintaining national stem cell transplantation database
7. NIH awards Georgia malaria research consortium up to $19.4 million contract
8. Care2Learn/Upstairs Solutions and Jarlette Health Services Sign Multi-Year Contract for Online Training and Record-Keeping
9. NHS consultant contract fails to increase productivity
10. PLEXERA® LLC Launches Contract Research Services Business for Biomolecular Interaction Studies
11. Securityhunter, Inc. Selected as a Top 25 Baltimore Defense Contractor for the Baltimore Business Journal's 2013 Book of Lists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... SABRE is raising awareness about personal safety ... the end of November. , The Chicago, Illinois, based self-defense brand has been waiting ... about the ease of taking their personal safety into their own hands. , The ...
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional Communication:, ... http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of drug and device marketing and ... compliance with FDA rules. , The FDA has issued two draft guidances that ...
(Date:9/21/2017)... ... September 21, 2017 , ... Demonstrating a consistent and ... departments have been awarded five-year accreditation status through the Public Health Accreditation ... served by a PHAB-accredited health department now extend to more than 203 ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... right or exercise more try taking a more holistic approach and use natural ... new Amazon essential oil collection is certified USDA guaranteeing that, the new line ...
(Date:9/21/2017)... Mass. (PRWEB) , ... September 21, 2017 , ... The ... children with autism, announced today the election of Yie-Hsin Hung to the Board of ... Hung join our Board of Directors. Ms. Hung is an invaluable addition to our ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
(Date:9/9/2017)...  Eli Lilly and Company (NYSE: LLY ... for lasmiditan, an investigational, oral, first-in-class molecule for the ... compared to placebo in the Phase 3 SPARTAN study. ... Congress of the International Headache Society (IHC) in ... today demonstrate lasmiditan,s potential to reduce pain and provide ...
Breaking Medicine Technology: